🔎 Trials Near Me

Home › Burkitt Lymphoma › District of Columbia › Washington

Pag-aaral pangklinika para sa Burkitt Lymphoma sa Washington, DC

9 pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Washington (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2
  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
366 Days – 46 Years · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06124157

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Nagre-recruitPhase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05442515

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Nagre-recruitPhase 2
  • MedStar Georgetown University Hospital, Washington D.C.
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03739814

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Nagre-recruitPhase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Nagre-recruitPhase 3
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2
  • Children's National Medical Center, Washington D.C.
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Nagre-recruitPhase 3
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Nagre-recruitPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05389423

Pag-aaral para sa Burkitt Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Washington

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.